索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]王健,刘广忠,白楠,等.二甲双胍在心血管疾病防治中的作用[J].国际心血管病杂志,2021,01:13-16,21.
点击复制

二甲双胍在心血管疾病防治中的作用(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2021年01期
页码:
13-16,21
栏目:
综述
出版日期:
2021-01-20

文章信息/Info

Title:
-
作者:
王健; 刘广忠; 白楠; 李为民
150001 哈尔滨医科大学附属第一医院心血管内科
Author(s):
-
关键词:
二甲双胍;  心力衰竭;  肺动脉高压;  心肌炎;  肿瘤心脏病;  心脏移植
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2021.01.004
文献标识码:
-
摘要:
二甲双胍是经典的降血糖药,同时还可用于防治心血管疾病,可用于心力衰竭、肺动脉高压、心肌炎、肿瘤心脏病等患者,延缓心血管疾病进展。该文介绍二甲双胍在心血管疾病中的作用及药理作用机制
Abstract:
-

参考文献/References

[1] 胡盛寿, 高润霖, 刘力生, 等. 《中国心血管病报告2018》概要[J]. 中国循环杂志, 2019, 34(3):209-220.
[2] 母义明, 纪立农, 宁光, 等. 二甲双胍临床应用专家共识(2018年版)[J]. 中国糖尿病杂志, 2019, 27(3):161-173.
[3] 柏华, 宋璇婧. 二甲双胍临床应用现状及进展[J]. 临床合理用药杂志, 2019, 12(16):175-177.
[4] Driver C, Bamitale K, Kazi A, et al. Cardioprotective effects of metformin[J]. J Cardiovasc Pharmacol, 2018, 72(2):121-127.
[5] Nesti L, Natali A. Metformin effects on the heart and the cardiovascular system: a review of experimental and clinical data[J]. Nutr Metab Cardiovasc Dis, 2017, 27(8):657-669.
[6] Dziubak A, Wójcicka G, Wojtak A, et al. Metabolic effects of metformin in the failing heart[J]. Int J Mol Sci, 2018, 19(10):2869.
[7] Weir DL, Abrahamowicz M, Beauchamp ME, et al. Acute vs cumulative benefits of metformin use in patients with type 2 diabetes and heart failure[J]. Diabetes Obes Metab, 2018, 20(11):2653-2660.
[8] Dludla PV, Nyambuya TM, Johnson R, et al. Metformin and heart failure-related outcomes in patients with or without diabetes: a systematic review of randomized controlled trials[J]. Heart Fail Rev, 2020, Mar 10. [Epub ahead of print].
[9] Larsen AH, Jessen N, Nrrelund H, et al. A randomised, double-blind, placebo-controlled trial of metformin on myocardial efficiency in insulin-resistant chronic heart failure patients without diabetes[J]. Eur J Heart Fail, 2020, 22(9):1628-1637.
[10] Gu J, Yin ZF, Zhang JF, et al. Association between long-term prescription of metformin and the progression of heart failure with preserved ejection fraction in patients with type 2 diabetes mellitus and hypertension[J]. Int J Cardiol, 2020, 306:140-145.
[11] Dean A, Nilsen M, Loughlin L, et al. Metformin reverses development of pulmonary hypertension via aromatase inhibition[J]. Hypertension, 2016, 68(2):446-454.
[12] Omura J, Satoh K, Kikuchi N, et al. Protective roles of endothelial AMP-activated protein kinase against hypoxia-induced pulmonary hypertension in mice[J]. Circ Res, 2016, 119(2):197-209.
[13] Liu Y, Xu Y, Zhu J, et al. Metformin prevents progression of experimental pulmonary hypertension via inhibition of autophagy and activation of adenosine monophosphate-activated protein kinase[J]. J Vasc Res, 2019, 56(3):117-128.
[14] Sun Z, Liu Y, Yu F, et al. Long non-coding RNA and mRNA profile analysis of metformin to reverse the pulmonary hypertension vascular remodeling induced by monocrotaline[J]. Biomed Pharmacother, 2019, 115:108933.
[15] Liao S, Li D, Hui Z, et al. Chronic dosing with metformin plus bosentan decreases in vitro pulmonary artery contraction from isolated arteries in adults with pulmonary hypertension[J]. J Cardiovasc Thorac Res, 2019, 11(3):189-195.
[16] Xie W, Wang L, Dai Q, et al. Activation of AMPK restricts coxsackievirus B3 replication by inhibiting lipid accumulation[J]. J Mol Cell Cardiol, 2015, 85:155-167.
[17] Li M, Gou Y, Yu H, et al. Mechanism of metformin on LPS-induced bacterial myocarditis[J]. Dose Response, 2019, 17(2):1559325819847409.
[18] Li M, Yu H, Wang Y, et al. Role of IRF4 in the protection of metformin-mediated sepsis myocarditis[J]. Dose Response, 2019, 17(1):1559325819827436.
[19] Tzanavari T, Varela A, Theocharis S, et al. Metformin protects against infection-induced myocardial dysfunction[J]. Metabolism, 2016, 65(10):1447-1458.
[20] Ajzashokouhi AH, Bostan HB, Jomezadeh V, et al. A review on the cardioprotective mechanisms of metformin against doxorubicin[J]. Hum Exp Toxicol, 2020, 39(3):237-248.
[21] Wang L, Shi W, Gao X, et al. Cardioprotective role of metformin against sodium arsenite-induced oxidative stress, inflammation, and apoptosis[J]. IUBMB Life, 2020, 72(4):749-757.
[22] Yu JM, Hsieh MC, Qin L, et al. Metformin reduces radiation-induced cardiac toxicity risk in patients having breast cancer[J]. Am J Cancer Res, 2019, 9(5):1017-1026.
[23] Peled Y, Lavee J, Raichlin E, et al. Metformin therapy reduces the risk of malignancy after heart transplantation[J]. J Heart Lung Transplant, 2017, 36(12):1350-1357.
[24] Ram E, Lavee J, Tenenbaum A, et al. Metformin therapy in patients with diabetes mellitus is associated with a reduced risk of vasculopathy and cardiovascular mortality after heart transplantation[J]. Cardiovasc Diabetol, 2019, 18(1):118.
[25] Chin JT, Troke JJ, Kimura N, et al. A novel cardioprotective agent in cardiac transplantation: metformin activation of AMP-activated protein kinase decreases acute ischemia-reperfusion injury and chronic rejection[J]. Yale J Biol Med, 2011, 84(4):423-432.
[26] Kinoshita S, Hosomi K, Yokoyama S, et al. Inverse association between metformin and amiodarone-associated extracardiac adverse events[J]. Int J Med Sci, 2020, 17(3):302-309.
[27] Hanai J, Cao P, Tanksale P, et al. The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity[J]. J Clin Invest, 2007, 117(12):3940-3951.
[28] Elsaid O, Taylor B, Zaleski A, et al. Rationale for investigating metformin as a protectant against statin-associated muscle symptoms[J]. J Clin Lipidol, 2017, 11(5):1145-1151.
[29] Raffort J, Hassen-Khodja R, Jean-Baptiste E, et al. Relationship between metformin and abdominal aortic aneurysm[J]. J Vasc Surg, 2020, 71(3):1056-1062.
[30] Chen Y, Su X, Qin Q, et al. Metformin inhibited homocysteine-induced upregulation of endothelin receptors through the Sirt1/NF-κB signaling pathway in vascular smooth muscle cells[J]. Vascul Pharmacol, 2020, 124:106613.
[31] Li B, Po SS, Zhang B, et al. Metformin regulates adiponectin signalling in epicardial adipose tissue and reduces atrial fibrillation vulnerability[J]. J Cell Mol Med, 2020, 24(14):7751-7766.
[32] Li J, Li B, Bai F, et al. Metformin therapy confers cardioprotection against the remodeling of gap junction in tachycardia-induced atrial fibrillation dog model[J]. Life Sci, 2020, 254:117759.

备注/Memo

备注/Memo:
基金项目:国家自然科学基金项目(81270252)
通信作者:李为民,E-mail:Liweimin_2009@126.com
更新日期/Last Update: 2021-01-20